Comprehensive clinical trial delivery across Phase I–III with a focus on quality and efficiency.
Mo is CEO of hVIVO with over 25 years of experience in clinical research and the CRO industry.
Mo has worked as a consultant assisting CROs to develop growth strategies and helping prepare companies for future expansion, both organic and through M&A activity.
In addition, Mo worked with Private Equity firms providing insight in identifying potential targets and conducting due diligence in preparation for M&A activity.
Prior to this Mo had a variety of senior roles at Pharm-Olam where he played a pivotal role in growing a small niche clinical monitoring business to a global full-service CRO with offices across all continents.
In his time at Pharm-Olam Mo had leading roles in Clinical Operations, Project Management, Business Development and Executive Management functions.
As a key member of the Executive Team Mo participated in the successful sale of the company in 2017, delivering substantial returns to its shareholders. Prior to this he worked at Innovex and Quintiles (IQVIA).
No articles found for this topic.
